Prenetics Global (NASDAQ:PRE) Stock Gets Price Target Cut from B. Riley Financial

Prenetics Global (NASDAQ:PRE – Get Free Report) had its target price lowered by equities researchers at B. Riley Financial from $37.00 to $31.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. B. Riley Financial‘s price target would suggest a potential upside of 192.18% from the company’s current price.

Several other research firms have also recently commented on PRE. Maxim Group began coverage on Prenetics Global in a research report on Monday, October 26th. They issued a “buy” rating and a $41.00 target price on the stock. Craig Hallum assumed coverage on Prenetics Global in a research report on Thursday, September 17th. They set a “buy” rating and a $40.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, October 15th. Wall Street Zen raised Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Lucid Cap Mkts raised Prenetics Global to a “strong-buy” rating in a report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Prenetics Global has an average rating of “Moderate Buy” and an average target price of $36.17.

Read Our Latest Research Report on PRE

Prenetics Global Stock Performance

Shares of NASDAQ:PRE traded up $0.26 during trading hours on Thursday, hitting $10.61. The stock had a trading volume of 373,013 shares, compared to its average volume of 232,161. The stock’s fifty day simple moving average is $19.80 and its 200 day simple moving average is $19.48. Prenetics Global has a 1-year low of $9.13 and a 1-year high of $27.24. The firm has a market capitalization of $179.03 million, a price-to-earnings ratio of -2.50 and a beta of 0.40.

Prenetics Global (NASDAQ:PRE – Get Free Report) last released its quarterly earnings results on Sunday, November 1st. The company reported ($1.45) earnings per share for the quarter. The business had revenue of $64.11 million for the quarter. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. As a group, research analysts anticipate that Prenetics Global will post -2.36 EPS for the current year.

Insider Buying and Selling

In related news, CEO Danny Sheng Wu Yeung acquired 17,181 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were acquired at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the purchase, the chief executive officer directly owned 112,416 shares of the company’s stock, valued at $2,386,591.68. The trade was a 18.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Brian J. Rosin acquired 5,100 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were bought at an average price of $22.80 per share, for a total transaction of $116,280.00. Following the purchase, the chief financial officer directly owned 23,100 shares of the company’s stock, valued at approximately $526,680. This trade represents a 28.33% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 40,281 shares of company stock valued at $862,453. Company insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Prenetics Global

A number of institutional investors have recently added to or reduced their stakes in PRE. Prospect Capital Advisors LLC bought a new position in Prenetics Global during the third quarter valued at about $9,279,000. Pillsbury Lake Capital LLC acquired a new position in Prenetics Global during the third quarter worth about $4,407,000. Marshall Wace LLP bought a new stake in Prenetics Global in the third quarter worth about $3,643,000. Renaissance Technologies LLC raised its position in Prenetics Global by 85.1% in the first quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock worth $605,000 after acquiring an additional 14,400 shares in the last quarter. Finally, State Street Corp bought a new stake in Prenetics Global in the third quarter worth about $264,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Key Prenetics Global News

These are some of the PRE news items that stood out recently:

  • Positive Sentiment: Q3 revenue rose about 228% year over year to $64.1 million, beating both company guidance and analyst estimates. IM8 revenue increased 266% to $62.9 million, its seventh consecutive record quarter. Prenetics reaffirmed 2026 revenue guidance of $220–230 million and forecast IM8 revenue of more than $400 million in 2027. Prenetics Q3 results and guidance
  • Neutral Sentiment: Q4 revenue guidance of $73–83 million brackets the $78.6 million analyst consensus, offering no clear near-term sales surprise. Prenetics shares down on wider loss and lowered second-half guidance
  • Negative Sentiment: The quarterly loss was $25.4 million, and EPS of negative $0.93 missed the consensus estimate of negative $0.90. The company also raised its expected second-half adjusted EBITDA loss to $30–35 million from $8–12 million, citing increased customer-acquisition investment. That weaker profitability outlook is the main pressure on the stock despite strong sales growth. Prenetics shares down on wider loss and lowered second-half guidance

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

See Also

Analyst Recommendations for Prenetics Global (NASDAQ:PRE)

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.